The company has not filed an annual or quarterly report since its Q3 FY2022 10-Q, filed Nov 14, 2022. Its latest SEC filing is a 15-12G from Oct 4, 2023.
10-Q for Q3 FY2022, filed Nov 14, 2022
The sections below describe the company as of the FY2021 annual report.
Sells single-use molecular test kits for infectious diseases, including coronavirus, to consumers, healthcare providers and businesses.
10-K for FY2021, filed Mar 31, 2022We are a medical technology company on a mission to bring central laboratory quality testing for infectious diseases into the home and…View ↗
Our first commercially available PCR-quality diagnostic test was the LUCIRA COVID-19 All-In-One Test Kit, which received EUA from the FDA…View ↗
All of the Company’s revenue has been derived from sales of its test kits through its healthcare, business-to-business, international and…View ↗
Customers buy Lucira test kits; the company generally bills when kits ship, with payment collected within 30 days. Online buyers typically pay immediately or within a few days, while customers in some countries pay before delivery.
10-K for FY2021, filed Mar 31, 2022Under ASC 606, assuming all other revenue recognition criteria have been met, the Company will recognize revenue for arrangements upon the…View ↗
Collection of the Company’s net revenue generally occurs within 30 days of billing. Contracts do not contain significant financing…View ↗
The Company invoices its customers upon shipment of product and records its sales upon shipment in accordance with its standard terms and…View ↗
$93.1M
10-K for FY2021, filed Mar 31, 2022
$93.1M ↗
Healthcare providers buy through Lucira's healthcare channel; businesses and consumers buy through business-to-business and online channels, while international sales go through distributors.
10-K for FY2021, filed Mar 31, 2022All of the Company’s revenue has been derived from sales of its test kits through its healthcare, business-to-business, international and…View ↗
10-K for FY2021, filed Mar 31, 2022
No. It lost $64.8M in FY2021.
10-K for FY2021, filed Mar 31, 2022
−$65.1MView ↗
10-K for FY2021, filed Mar 31, 2022
−$64.8MView ↗
10-K for FY2021, filed Mar 31, 2022
−$116.3MView ↗
8-K, filed Sep 25, 2023
On September 13, 2023, the Company filed its Amended Chapter 11 Plan of Liquidation of Lucira Health, Inc. (the “Chapter 11 Plan”) with the…View ↗
8-K, filed Apr 24, 2023
On April 19, 2023, the Bankruptcy Court entered an order approving the sale of substantially all of the Company’s assets to the Buyer…View ↗
8-K, filed Feb 27, 2023
On February 23, 2023, the Company received written notice (the “Delisting Notice”) from the staff of the Nasdaq Stock Market LLC (“Nasdaq”)…View ↗
8-K, filed Feb 22, 2023
On February 22, 2023, Lucira Health, Inc. (the “Company”) filed a voluntary petition for relief under chapter 11 of title 11 of the United…View ↗
Competes with Quest Diagnostics, Laboratory Corporation of America, Cue Health, and Detect
10-K for FY2021, filed Mar 31, 2022In diagnostic testing, we anticipate facing competition from companies that have or are developing molecular tests (including centralized…View ↗
Loading...
